| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8411391 | Drug Discovery Today: Technologies | 2014 | 6 Pages |
Abstract
The use of small molecule BRAF inhibitors has revolutionized the treatment of advanced melanoma. Despite this, resistance is commonplace and associated with a median progression-free survival of >5 months. Major resistance mechanisms include reactivation of the MAPK pathway and increased PI3K/AKT signaling. Here we review some of the combination therapeutic strategies currently undergoing evaluation for the management of acquired drug resistance in melanoma.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
H. Eirik Haarberg, Keiran S.M. Smalley,